OBJECTIVE: We evaluated the effect of human bone marrow stromal cells (hBMSCs), human adipose tissue-derived mesenchymal stem cells (hAD-MSCs), and umbilical cord-derived mesenchymal stem cells (hUC-MSCs) in bone tissue engineering and identified a reliable cell source. STUDY DESIGN: Alkaline phosphatase (ALP) activity and quantitative polymerase chain reaction were used to evaluate osteogenic in vitro, X-ray and histologic analysis in vivo. RESULTS: hBMSCs exhibited strongest ALP staining, followed by hAD-MSCs and hUC-MSCs. At 7 days, hUC-MSCs and hAD-MSCs had higher expression of collagen type I and Runt-related transcription factor 2 than hBMSCs, and hUC-MSCs showed higher osteopontin expression. Bone structure was observed in the hUC-MSC group. Defects showed good healing in the hBMSC and hAD-MSC groups. Enhanced green fluorescent protein and osteopontin were detected in newly formed bone at 8 weeks. CONCLUSIONS: Our results suggested that hUC-MSCs and hAD-MSCs could be used for bone tissue engineering effectively; hUC-MSCs could serve as a new alternative cell source.
OBJECTIVE: We evaluated the effect of human bone marrow stromal cells (hBMSCs), human adipose tissue-derived mesenchymal stem cells (hAD-MSCs), and umbilical cord-derived mesenchymal stem cells (hUC-MSCs) in bone tissue engineering and identified a reliable cell source. STUDY DESIGN:Alkaline phosphatase (ALP) activity and quantitative polymerase chain reaction were used to evaluate osteogenic in vitro, X-ray and histologic analysis in vivo. RESULTS: hBMSCs exhibited strongest ALP staining, followed by hAD-MSCs and hUC-MSCs. At 7 days, hUC-MSCs and hAD-MSCs had higher expression of collagen type I and Runt-related transcription factor 2 than hBMSCs, and hUC-MSCs showed higher osteopontin expression. Bone structure was observed in the hUC-MSC group. Defects showed good healing in the hBMSC and hAD-MSC groups. Enhanced green fluorescent protein and osteopontin were detected in newly formed bone at 8 weeks. CONCLUSIONS: Our results suggested that hUC-MSCs and hAD-MSCs could be used for bone tissue engineering effectively; hUC-MSCs could serve as a new alternative cell source.
Authors: Jinling Ma; Sanne K Both; Fang Yang; Fu-Zhai Cui; Juli Pan; Gert J Meijer; John A Jansen; Jeroen J J P van den Beucken Journal: Stem Cells Transl Med Date: 2013-12-03 Impact factor: 6.940
Authors: Cody C Wyles; Matthew T Houdek; Ruben J Crespo-Diaz; German A Norambuena; Paul G Stalboerger; Andre Terzic; Atta Behfar; Rafael J Sierra Journal: Clin Orthop Relat Res Date: 2015-06-13 Impact factor: 4.176
Authors: Sofia Bougioukli; Osamu Sugiyama; William Pannell; Brandon Ortega; Matthew H Tan; Amy H Tang; Robert Yoho; Daniel A Oakes; Jay R Lieberman Journal: Hum Gene Ther Date: 2018-03-14 Impact factor: 5.695
Authors: Faisal E Al Jofi; Tao Ma; Dong Guo; Monica P Schneider; Yan Shu; Hockin H K Xu; Abraham Schneider Journal: Cytotherapy Date: 2018-03-16 Impact factor: 5.414
Authors: Ildeu H L Pereira; Eliane Ayres; Luc Averous; Guy Schlatter; Anne Hebraud; Ana Cláudia Chagas de Paula; Pedro Henrique Leroy Viana; Alfredo Miranda Goes; Rodrigo L Oréfice Journal: J Mater Sci Mater Med Date: 2013-12-31 Impact factor: 3.896